nivolumab,ipilimumab
bms
['rectal', 'colorectal', 'niche-2']
just out at #esmo22 by our colleague niche-2 for tx naive dmmr #colorectalcancer, nonmetastatic, demonstrates &gt; 95% major path response after short term #immunotherapy treatment. 
?? Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees ?? We are #OncoAlert ??